{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:47:12Z","timestamp":1791697632530,"version":"4.3.4"},"reference-count":52,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel CD3\u00d7CD20 bispecific antibody (BsAb) immunotherapies have entered the armamentarium for follicular lymphoma and diffuse large B-cell lymphoma based on accelerated approvals. The primary challenge in utilizing BsAbs lies in patient selection due to variable responses, unique toxicity, and health economics. To date, no validated biomarkers of therapy response exist, however data demonstrating potential clinical, imaging, and biological markers relating to BsAbs are growing. This review examines current prognostic and potentially predictive biomarkers and explores future directions for nuanced patient selection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025772","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T21:03:16Z","timestamp":1739394196000},"page":"1850-1857","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Emerging biomarkers for CD3\u00d7CD20 bispecific antibodies in lymphoma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-8096","authenticated-orcid":false,"given":"Cameron S.","family":"Lewis","sequence":"first","affiliation":[{"name":"1Department of Hematology, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0540","authenticated-orcid":false,"given":"Allison","family":"Barraclough","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Fiona Stanley Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Austin Health, Melbourne, Australia"},{"name":"3Olivia Newton-John Cancer Research Institute, La Trobe University, Melbourne, Australia"},{"name":"4School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2025051414570122400_bib1","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"287","key":"2025051414570122400_bib2","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell\u2013dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"17","key":"2025051414570122400_bib3","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"2025051414570122400_bib4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2025051414570122400_bib5","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2025051414570122400_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL) [abstract]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2025051414570122400_bib7","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025051414570122400_bib8","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-Eegaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2025051414570122400_bib9","doi-asserted-by":"crossref","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"eBioMedicine"},{"issue":"suppl 1","key":"2025051414570122400_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) [abstract]","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025051414570122400_bib11","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025051414570122400_bib12","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A\u00a0novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"issue":"11","key":"2025051414570122400_bib13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2025051414570122400_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2023-184883","article-title":"Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-cell lymphoma [abstract]","volume":"142","author":"Iacoboni","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2025051414570122400_bib15","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1182\/bloodadvances.2023010840","article-title":"Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study","volume":"7","author":"Olszewski","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025051414570122400_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025051414570122400_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2023-173951","article-title":"Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume [abstract]","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025051414570122400_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051414570122400_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2024-201626","article-title":"Efficacy, toxicity, and predictors of outcomes with CD3-CD20 bi-specific antibodies post CAR T-cell failure for aggressive B-cell lymphoma [abstract]","volume":"144","author":"Melody","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025051414570122400_bib20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025051414570122400_bib21","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2023-186072","article-title":"Resistance mechanisms impacting bispecific antibody (BsAbs) and chimeric antigen receptor (CAR) T-cell therapy outcomes in large B cell lymphoma (LBCL) patients [abstract]","volume":"142","author":"Iraola-Truchuelo","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025051414570122400_bib22","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"2025051414570122400_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025051414570122400_bib24","doi-asserted-by":"crossref","first-page":"e008338","DOI":"10.1136\/jitc-2023-008338","article-title":"Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"12","author":"Brouwer-Visser","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl","key":"2025051414570122400_bib25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/01.HS9.0000847704.12245.1f","article-title":"Immune correlates of response to glofitamab: biomarker findings from a pivotal phase II expansion study in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"6","author":"Piccione","year":"2022","journal-title":"HemaSphere"},{"issue":"6","key":"2025051414570122400_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2025051414570122400_bib27","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"suppl","key":"2025051414570122400_bib28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/01.HS9.0000847372.57687.d4","article-title":"Mosunetuzumab is efficacious and well tolerated in patients aged &lt;65 and \u226565 with relapsed\/refractory follicular lymphoma and \u22652 prior therapies: subgroup analysis of a pivotal phase II study","volume":"6","author":"Matasar","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2025051414570122400_bib29","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2023-180246","article-title":"Epcoritamab SC + GemOx Leads to high complete metabolic response rates in patients with relapsed\/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant: updated results from Epcore NHL-2 [abstract]","volume":"142","author":"Brody","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051414570122400_bib30","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/blood-2022-159594","article-title":"Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged &lt;65 and \u226565 years with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) and \u22651 prior therapy: subgroup analysis of a phase Ib\/II study [abstract]","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051414570122400_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma [abstract]","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051414570122400_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2024-198883","article-title":"Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed\/refractory large B-cell lymphoma [abstract]","volume":"144","author":"Shumilov","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2025051414570122400_bib33","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","article-title":"The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas","volume":"8","author":"Haydu","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025051414570122400_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2025051414570122400_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051414570122400_bib36","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2024-199799","article-title":"Prior bendamustine (benda) exposure did not impact clinical outcomes and decreased CD4+ but not CD8+ T-cells in patients with diffuse large B-cell lymphoma (DLBCL) treated with the bispecific antibody epcoritamab (epcor) [abstract]","volume":"144","author":"Phillips","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051414570122400_bib37","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2024-205671","article-title":"Impact of prior bendamustine exposure on bispecific antibody treatment outcomes in patients with relapsed\/refractory follicular lymphoma [abstract]","volume":"144","author":"Iacoboni","year":"2024","journal-title":"Blood"},{"issue":"20","key":"2025051414570122400_bib38","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2023020400","article-title":"Alternative splicing of its 5\u2019-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies","volume":"142","author":"Ang","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025051414570122400_bib39","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2025051414570122400_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment","volume":"11","author":"van der Horst","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025051414570122400_bib41","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.02.24309792","article-title":"Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas","author":"Falchi","year":"5  2024","journal-title":"medRxiv"},{"issue":"1","key":"2025051414570122400_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2025051414570122400_bib43","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025051414570122400_bib44","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1186\/s12885-022-10070-z","article-title":"EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker\u00a0to guide frontline treatment. [published correction appears in BMC Cancer. 2022;22(1):1224]","volume":"22","author":"Mart\u00ednez-Laperche","year":"2022","journal-title":"BMC Cancer"},{"issue":"8","key":"2025051414570122400_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2025051414570122400_bib46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T\u00a0cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"2025051414570122400_bib47","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025051414570122400_bib48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion.\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2025051414570122400_bib49","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3390\/cancers13092225","article-title":"Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of CAR-T cell therapies","volume":"13","author":"Truong","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"2025051414570122400_bib50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. [published correction appears in Blood Cancer Discov. 2022;3(1):82]","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"2025051414570122400_bib51","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025051414570122400_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1850\/2370330\/blood_bld-2024-025772-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1850\/2370330\/blood_bld-2024-025772-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T18:58:25Z","timestamp":1747249105000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/17\/1850\/535578\/Emerging-biomarkers-for-CD3-CD20-bispecific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":52,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025772","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,24]]},"published":{"date-parts":[[2025,4,24]]}}}